# Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

> **NCT03042312** · PHASE2 · TERMINATED · sponsor: **Endocyte** · enrollment: 71 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT03042312
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-12
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Recruitment was stopped before the target sample size was achieved.
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042312, "Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03042312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*